These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30727912)

  • 1. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.
    Singh M; Sharma R; Kumar A
    Curr Drug Saf; 2019; 14(2):87-93. PubMed ID: 30727912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
    Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
    Perm J; 2021 May; 25():. PubMed ID: 33970086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.
    Ueda M; Zenibayashi M; Yamada T; Asahara SI; Ogawa W
    Kobe J Med Sci; 2024 Jul; 70(3):E81-E88. PubMed ID: 39107964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
    Bersoff-Matcha SJ; Chamberlain C; Cao C; Kortepeter C; Chong WH
    Ann Intern Med; 2019 Jun; 170(11):764-769. PubMed ID: 31060053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
    Ren DY; Zhang Y
    Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
    Yang Y; Zhao C; Ye Y; Yu M; Qu X
    Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
    Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
    Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
    Liu Y; An C; Liu P; Yang F; Zhao Q
    Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
    McGill JB; Subramanian S
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of SGLT2 Inhibitors in Three Chronic Diseases.
    Ge S; Liu R; Mao Y; Geng C; Wang H; Song K; Tian QB
    Int Heart J; 2023; 64(2):246-251. PubMed ID: 37005318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the safety of SGLT2 inhibitors.
    Scheen AJ
    Expert Opin Drug Saf; 2019 Apr; 18(4):295-311. PubMed ID: 30933547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.
    Bartolo C; Hall V; Friedman ND; Lanyon C; Fuller A; Morrissey CO; Athan E
    BMC Infect Dis; 2021 Mar; 21(1):284. PubMed ID: 33743624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.
    Mashraqi MM; Chaturvedi N; Alam Q; Alshamrani S; Bahnass MM; Ahmad K; Alqosaibi AI; Alnamshan MM; Ahmad SS; Beg MMA; Mishra A; Shaikh S; Rizvi SMD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.